Special Issue "MicroRNAs as Biomarkers of Brain Dysfunction in Aging, Dementias, and Psychoses"

A special issue of Non-Coding RNA (ISSN 2311-553X).

Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 499

Special Issue Editors

Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Interests: neuropathology; biomarkers of neurodegeneration
Special Issues, Collections and Topics in MDPI journals
Department for Psychiatry and Psychotherapy, German Center for Neurodegenerative Diseases (DZNE), University Medical Center Göttingen, 37075 Göttingen, Germany
Interests: neurodegenerative disease; epigenetics; non-coding RNA; genome-environment interactions

Special Issue Information

Dear Colleagues,

Small non-coding RNA molecules (microRNAs, miRNAs) regulate genes involved in brain functions negatively affected in normal aging well as in neurodegenerative and neuropsychiatric diseases.

Although aging is the greatest risk for major neurodegenerative diseases, sociological, medical, and nutritional factors are thought to play a role and modulate the pace of cognitive decline and influence the risk for psychoses development.

Animal models suggest specific pathways through which genomic and epigenomic interaction affects neuroinflammation, cerebral lipid metabolism, brain insulin resistance, and myelin disintegration. Small non-coding RNAs (ncRNAs) regulate gene expression in response to genome–environment interactions. There is now accumulated evidence that microRNAs (miRNAs) may serve as prognostic and diagnostic biomarkers with mechanistic insights into the pathophysiologic processes, especially in the case of Alzheimer’s disease-associated cognitive decline, years before the clinical manifestation of the disease. Mechanistic approaches towards the design of novel preventive and therapeutic interventions will be enabled by the integration of the data from: (1) the ongoing large epidemiologic studies on the correlation of cognitive and behavioral changes in densely phenotyped individuals with plasma miRNAome; (2) the studies evaluating the relationship between the expression of a circulating miRNA biomarker and the expression of that biomarker in the brain cells; and (3) the investigation of the functional consequences of a human disease miRNA biomarker in animal models.

Prof. Dr. Ivana Delalle
Prof. Dr. André Fischer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neurodegeneration
  • cognitive decline
  • biomarker
  • small non-coding RNA
  • circulating microRNAs

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop